AERA Pediatrics Registry
Launched by INTEGRA LIFESCIENCES CORPORATION · Jul 8, 2025
Trial Information
Current as of September 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well the AERA® device works for children with problems related to the Eustachian tube, which is a small passage that helps equalize ear pressure and drain fluid. The study is collecting real-world information from multiple centers to see how the device performs in everyday use. It is currently open and looking for participants under the age of 18 who have a clear reason to try Eustachian tube balloon dilation (ETBD) using the AERA® device.
Children who have already had this procedure done with the AERA® device and meet the specific medical reasons for ETBD may be eligible to join. However, children who have had ETBD with a different device or have had the procedure before are not included. If your child participates, doctors will observe and record how the device works during their treatment without changing their usual care. This study helps gather important information to make sure this treatment is safe and effective for kids who need it.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \<18
- • 2. Specific indications for ETBD are documented
- • 3. ETBD with AERA device attempted-
- Exclusion Criteria:
- • 1. ETBD with device other than AERA®
- • 2. Previous ETBD procedure-
About Integra Lifesciences Corporation
Integra LifeSciences Corporation is a leading global medical technology company specializing in regenerative medicine and neurosurgery. With a commitment to innovation and excellence, Integra develops a diverse range of advanced technologies and products designed to improve patient outcomes in areas such as tissue regeneration, surgical reconstruction, and advanced wound care. The company is dedicated to supporting healthcare professionals through clinical trials that aim to validate the safety and efficacy of its cutting-edge solutions, ultimately enhancing the quality of care for patients worldwide. Integra’s focus on research and development, coupled with its robust portfolio, positions it as a key player in the medical device industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
West Bloomfield, Michigan, United States
Fort Worth, Texas, United States
Patients applied
Trial Officials
Christopher Schutt, MD
Study Director
Acclarent, an Integra LifeSciences Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported